Topline in line with expectation: Biocon posted its Q4 FY09 numbers. The topline of the company grew at a robust rate of 76% to Rs 468 crore compared to Rs 266.6 crore. The bio pharma segment of Biocon recorded a growth of 86.6% to …
Latest Query
- by Sam
Search Our Archives
Research Desk
- Stocks Trading above their 50 day moving average - DMA In Stock Research
- Download free Ebooks based on Technical Analysis In Personal Training
- TOP 100 Stocks with the Highest P/E as on July 14th, 2013 In Stock Research
- TOP 100 Stocks with the Lowest P/E as on July 14th, 2013 In Stock Research
- Charting Pathsala - Your guide to Techincals In Technical Analysis